USFDA27 Feb 2025, 09:36 pm
Granules India Receives Warning Letter from US FDA for Gagillapur Facility, Assures Compliance
AI Summary
Granules India Ltd. has received a Warning Letter from the US FDA for its Gagillapur facility, following an inspection in August 2024 and the classification of the facility as 'Official Action Indicated' (OAI). The FDA has not indicated any further escalation. The company is confident that the matter will be resolved satisfactorily within a reasonable timeframe. The Warning Letter may temporarily impact the FDA review of pending product submissions from this site. Granules has implemented a remediation plan, engaged independent consulting firms, and is providing regular updates to the FDA. The company's growth trajectory remains robust, with diversified key drivers ensuring sustained performance.
Key Highlights
- Granules India Ltd. receives Warning Letter from US FDA for Gagillapur facility
- FDA has not indicated further escalation
- Company confident of satisfactory resolution within reasonable timeframe
- Remediation plan implemented, independent consulting firms engaged
- Company growth trajectory robust with diversified key drivers